News

SITC 2024: Update on Use of HDAC Inhibitor Plus Nivolumab in Advanced Melanoma

SITC 2024: Addition of Radiotherapy to Immunotherapy in Advanced Merkel Cell Carcinoma

SITC 2024: Comparing Types of Tumor Infiltrating Lymphocytes in Merkel Cell Carcinoma

Does Skin Screening Alter the Incidence of Skin Cancer? Australian Researchers Weigh In

SITC 2024: Potential Biomarker of Disease Progression After Immunotherapy for Advanced Melanoma

SITC 2024: Efficacy Outcomes With TIL Therapy for Advanced Melanoma

Radiotherapy for Merkel Cell Carcinoma: Hypofractionated vs Standard Fractionation

Pediatric Cutaneous Melanoma: Recommendations for Diagnosis and Treatment

Is Immunotherapy Efficacious for Children and Adolescents With Melanoma?

Calculating Risk of Dermatologic Concerns After Solid Organ Transplantation

Surgical Strategies for Melanoma: Listening to the Patient Voice

Does Radiation Therapy for Thyroid Cancer Increase the Risk of Skin Cancers?

Treatment Resistance in Melanoma: Are Biological Sex Differences at Play?

Can Teledermatology Improve Time to Diagnosis Among Chilean Patients With Skin Cancer?

Does Age Impact Recurrence After Image-Guided Superficial Radiotherapy for Skin Cancers?

Does Low-Count Monoclonal B-Cell Lymphocytosis Increase the Risk of Melanoma?

What’s in a Name? ‘Keratinocyte Cancer’ or ‘Non-Melanoma Skin Cancer’

Does Adjuvant Therapy Impact Overall Survival in Stage III Melanoma?

ESMO 2024: Long-Term Survival Update for INMC Pooled Analysis of Neoadjuvant Therapy in Melanoma

ESMO 2024: Hypomethylation Plus Immune Checkpoint Inhibition for Metastatic Melanoma

Are U.S. Veterans at Risk for Developing Skin Cancer? Researchers Investigate

ESMO 2024: 10-Year Outcomes With Pembrolizumab vs Ipilimumab in Advanced Melanoma

Mohs Micrographic Surgery in High-Risk Basal Cell Carcinoma

ESMO 2024: Immune Checkpoint Inhibition Following Targeted Therapy for Advanced Melanoma

ESMO 2024: Final Results From CheckMate 067 of Nivolumab Plus Ipilimumab in Advanced Melanoma

ESMO 2024: Sotigalimab Plus Pembrolizumab in Metastatic Melanoma

Effects of UVA vs UVB Exposure on Melanoma Risk

Long-Term Health-Related Quality of Life With Adjuvant Pembrolizumab in Stage III Melanoma

Survival Outcomes in BRAF-Mutant Melanoma: BRAF/MEK vs PD-1 Inhibitors

BRAF-Mutated Metastatic Melanoma: Predicting Therapeutic Response With ctDNA

Early Results of Combination Regimens With Pembrolizumab in Melanoma

4-Year Follow-up on Lenvatinib Plus Pembrolizumab in Advanced Melanoma

Can FDG-PET Predict Survival and Response to Neoadjuvant Immunotherapy in Melanoma?

Role of Cancer Cell Plasticity in Response to Immunotherapy in Cutaneous Squamous Cell Carcinoma

Nivolumab Plus Relatlimab in Melanoma: 3-Year Survival Outcomes From RELATIVITY-047

MEK Inhibitor in NRAS-Mutated Melanoma: Phase II Trial Update

Lifetime Prevalence of Skin Cancer and Sexual Orientation: Differences by Race and Ethnicity?

Novel Immunotherapy Combination After Anti–PD-1 Therapy Fails in Advanced Melanoma

Stage pT1bN0 Cutaneous Melanoma: Prognostic Factors and Risk Groups

Nivolumab Delivered Through Continuous Intrathecal Infusion for Advanced Melanoma

Long-Term Results With Adjuvant Dabrafenib Plus Trametinib in BRAF-Mutated Melanoma

Tocilizumab Combined With Nivolumab and Ipilimumab in Advanced Melanoma

Exploring Treatment Options for Advanced-Stage Melanoma During Pregnancy

KEYNOTE-629: Long-Term Results With Pembrolizumab in Squamous Cell Skin Cancer

IL-2–Sparing Tumor-Infiltrating Lymphocyte Cell Therapy for Melanoma

Can Radiation Therapy Improve Disease-Specific Survival in Merkel Cell Carcinoma?

When Surgery’s Not an Option: Topical Imiquimod vs Radiotherapy for Lentigo Maligna

CXCR1/2 Inhibitor Plus Pembrolizumab in Metastatic Melanoma: Early-Phase Trial Results

Neoadjuvant Immunotherapy for Squamous Cell Skin Cancer

Lifileucel Plus Pembrolizumab Active in Melanoma Setting in Phase II Trial

Clinician Guidance on Resources for Patients Provided by AIM at Skin Cancer

Novel Monoclonal Antibody and Chemotherapy Under Study in Nonmelanoma Skin Cancer

Vaccine Plus Immunotherapies Under Investigation in Advanced Melanoma

mRNA Vaccine Under Study in Merkel Cell Carcinoma

Advanced Cutaneous Squamous Cell Carcinoma: Predicting Response to Immune Checkpoint Inhibitor Therapy

$600K Grant Awarded to Wistar Researcher to Study Impact of Microbial Genes on Immunotherapy Response in Melanoma

Neoadjuvant Use of Pembrolizumab in Locally Advanced Squamous Cell Skin Cancer

ASCO 2024: Impact of Discontinuing Immunotherapy After Response in Merkel Cell Carcinoma

ASCO 2024: Phase I Findings on Novel Bispecific Protein for Cutaneous Melanoma

ASCO 2024: Triplet Regimen Under Study in High-Risk, Resectable Melanoma

ASCO 2024: Learning About the Impact of Socioeconomic Factors on Superficial Basal Cell Carcinoma

ASCO 2024: KEYNOTE-942 Evaluates mRNA-4157 Plus Pembrolizumab in Resected Melanoma

ASCO 2024: Quality of Life With Neoadjuvant Immunotherapy for Stage III Melanoma

ASCO 2024: Use of Tilsotolimod Plus Ipilimumab vs Ipilimumab Alone in Advanced Melanoma

ASCO 2024: Immunotherapy for Ulcer-Related Squamous Cell Skin Cancer

ASCO 2024: BRAF and MEK Inhibitors Plus Immunotherapy for BRAF V600E/K–Mutated Melanoma

ASCO 2024: Intratumoral Daromun Under Study in Resectable Metastatic Melanoma

ASCO 2024: Risk-Adapted Surgical De-escalation for Resectable Squamous Cell Carcinoma

ASCO 2024: Staging and Treating High-Risk Cutaneous Melanoma During Pregnancy

ASCO 2024: Triplet Immunotherapy Regimen Focus of Study in Advanced Melanoma

ASCO 2024: Phase III Trial Evaluates Neoadjuvant Immunotherapy for Stage III Melanoma

Primary and Metastatic Melanomas: Melanocortin-1 Receptor as Potential Therapeutic Target